The article discusses the challenges small and mid-sized companies are facing when taking AAV vector-based innovations from the laboratory bench to the clinic. While in-house manufacturing may be an option for some companies, partnering with a …
Affibody AB, a Swedish biotech company focused on developing next-generation biopharmaceuticals has selected Biovian Oy, the leading Nordic One-Stop-Shop CDMO for biopharmaceuticals as a CDMO partner for ABY-062 recombinant protein for clinical trial use. The …
We are pleased to let you know that Magnus Gustafsson from Biovian will speak about New Biologicals at “New Horizons in Biologics & Bioprocessing digital event”, on December 17th at 8:45 (CET). TALK: Manufacture and …
Discussion with Scientist Pekka Puolasmaa and Project Manager Tuomas Nikula. The goal of gene therapy is to treat or cure severe diseases by carrying genetic material to the target cells to repair the incorrect or …
To display how Finland and Finnish solutions participate in the fight against cancer, Business Finland has compiled a new digital booklet, providing an overview of the extensive know-how and current areas of innovation. Biovian’s CDMO …
A conversation with Pirjo Merilahti, PhD., Virology. At Biovian, Viral Vector process development is planned and executed by a team of experienced scientists, led by Dr Pirjo Merilahti. Her team typically starts the project with …
Take Advantage of One-on-One Partnering! Schedule a virtual meeting with Magnus Gustafsson, the Head of Global Business Development of Biovian and find out how we can help your gene therapy or biopharma project from the …
Biovian is delighted to announce that Dr. Magnus Gustafsson has been appointed Head of Global Business Development. “We are very pleased that Magnus Gustafsson will assume the role of Head of Global Business Development at …
In this video the CEO of Biovian, Knut Ringbom, presents an overview of the year 2020, especially discussing the latest developments in the company. “Over the last year, we have experienced a lot of positive …
The therapeutic possibilities of cell and gene therapy are very appealing. The possibility to use a Viral Vector to carry the therapeutic gene into the target cells or to initiate cell transduction holds the potential …
